Questcor Pharmaceuticals Inc (QCOR), Impax Laboratories Inc (IPXL): Two Stocks That Double Your Chances For Big Gains

Page 1 of 2

Virtually every investor is quite familiar with the names of big pharmaceutical giants such as GlaxoSmithKline plc (ADR) (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), and Abbott Laboratories (NYSE:ABT) and the fortunes that have been made by investors in these enormously successful businesses. What many investors fail to spend time considering is that a much of the growth of these large businesses came from buyouts of smaller faster growing companies within the pharmaceutical industry that were priced cheaply in comparison to their larger brethren.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

Special protection for special drugs

Certain drugs developed for the treatment of rare diseases (orphan drugs) are granted lower barriers for approval and/or extended patent protection as an incentive to manufacturers to produce them, thus limiting competition for market share. That is the upside; the downside is that the market for each drug is quite limited.

Mylan Inc. (NASDAQ:MYL) targets a portion of their business in orphan drugs to treat on/off fluctuations in people with Parkinson’s disease and a wound care product for the treatment of diabetic foot ulcers. In addition, they also have products for the treatment of migraine headaches that provide some exposure to a broader customer base. The diabetic treatment should allow for growth potential for their current sales volume of $6.84 billion, given the rapidly growing presence of the disease within the U.S. population, but there are some issues with the financial side of the business.

Mylan Inc. (NASDAQ:MYL) carries a debt to equity ratio of 2.18 and only generates enough cash to cover interest payments 4.3 times–not a tremendous cushion. In addition, its 5-year average returns on equity, assets, and capital have only been 7.1%, 2.8% and 3.4%, respectively, and its 5-year average net margin is a paltry 5.5%. These are not good numbers for any business outside of discount retail, but are very poor for the drug business.

Smaller and better, but more expensive

Impax Laboratories Inc (NASDAQ:IPXL) is a small ($1.29 billion market cap) generic drug manufacturer with current annual sales of $601 million. The company currently has 66 FDA approved Abbreviated New Drug Applications (ANDA’s), with an additional 39 pending. Furthermore, Impax has 79 more products in development, providing excellent forward growth potential as the pending applications are approved and new products move through the development stage.

The company carries no long term debt, as well as $349 million in cash and short term investments on hand against total liabilities of only $210.32, placing it is on a solid financial footing. While the 2013 price to earnings ratio of 117.5 is quite a bit higher than I would normally like to see, based on 2014 projected earnings of $0.57/share, it will fall to 32.98 and be closely aligned with the estimated 5-year growth rate of 26.9%. While this projection is a very aggressive rate of growth, the volume of products in the company’s pipeline does seem to justify the expectation. The past 5-year returns on equity, assets, and capital of 23%, 13.1%, and 16.8%, reveal an efficiently-run business with an exceptional ability to allocate capital effectively.

The projected rapid earnings growth and extensive product offerings and pipeline give Impax Laboratories Inc (NASDAQ:IPXL) the potential to produce very attractive returns for investors due to the business’s growth could also attract the attention of one of the larger generic manufacturers looking to grow through strategic acquisitions.

The cheapest price and most limited product line

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has one product, H.P. Acthar Gel, that accounts for approximately 95% of its $548.45 million in sales. Acthar Gel is an injectable product used in the treatment of infantile spasms and 18 other primary indications. Last fall, the share price was crushed when Aetna announced it would cease reimbursement for the drug when prescribed for multiple sclerosis and nephrotic syndrome, and investors feared other insurers would follow Aetna’s lead; however, that situation never developed. Widespread panic at the time sliced Questcor’s share price by almost 71%, from $58.91 to a low of $17.25. As fears of other insurers limiting reimbursement for the drug have subsided, the share price has rebounded to around $35/share now.

Page 1 of 2